scholarly journals CSMD1 gene mutations can lead to familial Parkinson disease

2017 ◽  
Vol 13 (11) ◽  
pp. 641-641 ◽  
Author(s):  
Mitesh Patel
2017 ◽  
Vol 3 (5) ◽  
pp. e177 ◽  
Author(s):  
Javier Ruiz-Martínez ◽  
Luis J. Azcona ◽  
Alberto Bergareche ◽  
Jose F. Martí-Massó ◽  
Coro Paisán-Ruiz

Objective:Despite the enormous advancements made in deciphering the genetic architecture of Parkinson disease (PD), the majority of PD is idiopathic, with single gene mutations explaining only a small proportion of the cases.Methods:In this study, we clinically evaluated 2 unrelated Spanish families diagnosed with PD, in which known PD genes were previously excluded, and performed whole-exome sequencing analyses in affected individuals for disease gene identification.Results:Patients were diagnosed with typical PD without relevant distinctive symptoms. Two different novel mutations were identified in the CSMD1 gene. The CSMD1 gene, which encodes a complement control protein that is known to participate in the complement activation and inflammation in the developing CNS, was previously shown to be associated with the risk of PD in a genome-wide association study.Conclusions:We conclude that the CSMD1 mutations identified in this study might be responsible for the PD phenotype observed in our examined patients. This, along with previous reported studies, may suggest the complement pathway as an important therapeutic target for PD and other neurodegenerative diseases.


2010 ◽  
Vol 16 (2) ◽  
pp. 136-138 ◽  
Author(s):  
Dariusz Koziorowski ◽  
Dorota Hoffman-Zacharska ◽  
Jarosław Sławek ◽  
Walentyna Szirkowiec ◽  
Piotr Janik ◽  
...  

2013 ◽  
Vol 17 (11) ◽  
pp. 826-832 ◽  
Author(s):  
Xiaowei Liu ◽  
Tao Ma ◽  
Bo Qu ◽  
Yan Ji ◽  
Zhi Liu

2020 ◽  
Vol 77 (4) ◽  
pp. 427 ◽  
Author(s):  
Stephen Mullin ◽  
Laura Smith ◽  
Katherine Lee ◽  
Gayle D’Souza ◽  
Philip Woodgate ◽  
...  

2014 ◽  
Vol 2014 ◽  
pp. 1-14 ◽  
Author(s):  
Soraya Scuderi ◽  
Valentina La Cognata ◽  
Filippo Drago ◽  
Sebastiano Cavallaro ◽  
Velia D'Agata

Parkinson protein 2, E3 ubiquitin protein ligase (PARK2) gene mutations are the most frequent causes of autosomal recessive early onset Parkinson’s disease and juvenile Parkinson disease. Parkin deficiency has also been linked to other human pathologies, for example, sporadic Parkinson disease, Alzheimer disease, autism, and cancer.PARK2primary transcript undergoes an extensive alternative splicing, which enhances transcriptomic diversification. To date severalPARK2splice variants have been identified; however, the expression and distribution of parkin isoforms have not been deeply investigated yet. Here, the currently knownPARK2gene transcripts and relative predicted encoded proteins in human, rat, and mouse are reviewed. By analyzing the literature, we highlight the existing data showing the presence of multiple parkin isoforms in the brain. Their expression emerges from conflicting results regarding the electrophoretic mobility of the protein, but it is also assumed from discrepant observations on the cellular and tissue distribution of parkin. Although the characterization of each predicted isoforms is complex, since they often diverge only for few amino acids, analysis of their expression patterns in the brain might account for the different pathogenetic effects linked toPARK2gene mutations.


Neurology ◽  
2006 ◽  
Vol 66 (3) ◽  
pp. 415-417 ◽  
Author(s):  
M. Toft ◽  
L. Pielsticker ◽  
O. A. Ross ◽  
J. O. Aasly ◽  
M. J. Farrer

Sign in / Sign up

Export Citation Format

Share Document